title: [Treatment of relapses and failures in disseminated Hodgkin's disease].
abstract: Treatment of disseminated Hodgkin's disease still fails in about 50 percent of the cases. The prognosis is poorer in case of early relapse or when the disease is refractory to first-line therapy from the start. Second- or third-line chemotherapy regimens have given rather disappointing results with a complete remission rate usually around 30 percent and a small number of cures. The indications for radiotherapy in localized lymph node relapses remain to be precisely determined. Based on the theoretical dose-effect concept, high-dose chemotherapy followed by autologous bone marrow transplantation increases the number of prolonged complete remissions in patients who respond to salvage chemotherapy. A wider use of haematopoietic growth factors should reduce the toxicity of this treatment.
authors.affiliation: Service d'Hématologie, Centre Hospitalier Lyon-Sud, Pierre-Bénite.
authors.forename: Y
authors.initials: Y
authors.lastname: Bastion
authors.forename: J D
authors.initials: JD
authors.lastname: Tigaud
authors.forename: B
authors.initials: B
authors.lastname: Coiffier
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000379:methods*; D002330:Carmustine / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D003606:Dacarbazine / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D015251:Epirubicin / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use; D008466:Mechlorethamine / Q000627:therapeutic use; D008558:Melphalan / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D008935:Mitoguazone / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D012074:Remission Induction; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D014747:Vinblastine; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D003561:Cytarabine; D001761:Bleomycin; D011344:Procarbazine; D015251:Epirubicin; D008466:Mechlorethamine; D014750:Vincristine; D014747:Vinblastine; D005047:Etoposide; D003606:Dacarbazine; D004317:Doxorubicin; D003520:Cyclophosphamide; D008935:Mitoguazone; D002945:Cisplatin; D008558:Melphalan; D002330:Carmustine; D007069:Ifosfamide; D011241:Prednisone; D008727:Methotrexate
vernacular_title: Traitement des rechutes et des échecs dans les formes disséminées de la maladie de Hodgkin.